Development and Validation of an Lc-Ms/Ms Method for the Determination of Sb-505124 in Rat Plasma: Application to Pharmacokinetic Study

Jiayu Jiang,Yuandong Zhang,Quan Zhang,Yanping Li,Tao Gong,Zhirong Zhang,Rui Ding,Xun Sun

DOI: https://doi.org/10.1016/j.jpba.2015.09.002

IF: 3.571

2016-01-01

Journal of Pharmaceutical and Biomedical Analysis

Abstract:A sensitive, selective and rapid liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-MS/MS) method has been developed for the quantification of the novel transforming growth factor-beta (TGF-beta) inhibitor SB-505124 in rat plasma and then validated. Plasma samples were prepared by simple protein precipitation. Separation was performed on a Diamonsil ODS chromatography column using a mobile phase of acetonitrile and 0.1% (v/v) aqueous formic acid. SB-505124 and the internal standard doxorubicin were detected in the positive ion mode using multiple reaction monitoring of the transitions at m/z 336.2 -> 320.1 and 544.2 -> 397.2, respectively. Calibration curve was linear (r>0.9996) over a concentration range of 10-5000 ng/mL with the lower quantification limit of 10 ng/mL. Both intra- and inter-day precision were within 6.5% and trueness were not more than 3.1%. Extraction recovery and matrix effect were within acceptable limits. Stability tests showed that SB-505124 and the IS remained stable throughout the analytical procedure. The validated LC-MS/MS method was then used to analyze the pharmacokinetics of SB-505124 administered to rats intravenously (8 mg/kg) or orally (10 mg/kg). Oral bioavailability of SB-505124 was calculated as 76.4%, indicating the potential of SB-505124 as an orally administered drug. (C) 2015 Elsevier B.V. All rights reserved.